Acrivon Therapeutics, Ownership
| ACRV Stock | 7.16 0.61 9.31% |
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.
Acrivon |
Acrivon Stock Ownership Analysis
About 22.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.04. Some equities with similar Price to Book (P/B) outperform the market in the long run. Acrivon Therapeutics, recorded a loss per share of 2.66. The entity had not issued any dividends in recent years. For more info on Acrivon Therapeutics, Common please contact the company at 617 207 8979 or go to https://www.acrivon.com.Besides selling stocks to institutional investors, Acrivon Therapeutics, also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Acrivon Therapeutics,'s stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Acrivon Therapeutics,'s strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Acrivon Therapeutics, Quarterly Liabilities And Stockholders Equity |
|
About 22.0% of Acrivon Therapeutics, Common are currently held by insiders. Unlike Acrivon Therapeutics,'s institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Acrivon Therapeutics,'s private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Acrivon Therapeutics,'s insider trades
Acrivon Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Acrivon Therapeutics, is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Acrivon Therapeutics, Common backward and forwards among themselves. Acrivon Therapeutics,'s institutional investor refers to the entity that pools money to purchase Acrivon Therapeutics,'s securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Dafna Capital Management Llc | 2024-09-30 | 112.4 K | Northern Trust Corp | 2024-09-30 | 105.4 K | Ubs O'connor Llc | 2024-09-30 | 79.2 K | Bridgeway Capital Management, Llc | 2024-09-30 | 77 K | Baker Bros Advisors Lp | 2024-09-30 | 52.9 K | Renaissance Technologies Corp | 2024-09-30 | 45.9 K | Exchange Traded Concepts, Llc | 2024-06-30 | 42.9 K | Springbok Capital Management, Llc | 2024-09-30 | 37.7 K | Bank Of New York Mellon Corp | 2024-06-30 | 36.6 K | Ra Capital Management, Llc | 2024-09-30 | 8.3 M | Perceptive Advisors Llc | 2024-09-30 | 5.4 M |
Acrivon Therapeutics, Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Acrivon Therapeutics, insiders, such as employees or executives, is commonly permitted as long as it does not rely on Acrivon Therapeutics,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Acrivon Therapeutics, insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Acrivon Therapeutics, Outstanding Bonds
Acrivon Therapeutics, issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Acrivon Therapeutics, uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Acrivon bonds can be classified according to their maturity, which is the date when Acrivon Therapeutics, Common has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| ACRISURE FINANCE INC Corp BondUS00489LAF04 | View | |
| Acrisure LLC 144A Corp BondUS00489LAH69 | View |
Acrivon Therapeutics, Corporate Filings
F4 | 18th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 13th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10Q | 13th of August 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
13A | 10th of July 2024 An amended filing to the original Schedule 13G | ViewVerify |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Acrivon Stock Analysis
When running Acrivon Therapeutics,'s price analysis, check to measure Acrivon Therapeutics,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acrivon Therapeutics, is operating at the current time. Most of Acrivon Therapeutics,'s value examination focuses on studying past and present price action to predict the probability of Acrivon Therapeutics,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acrivon Therapeutics,'s price. Additionally, you may evaluate how the addition of Acrivon Therapeutics, to your portfolios can decrease your overall portfolio volatility.